KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2025)

Historic FCF Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 2272.52%.

  • Recursion Pharmaceuticals' FCF Margin fell 20279600.0% to 2272.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 1024.72%, marking a year-over-year decrease of 5149500.0%. This contributed to the annual value of 633.71% for FY2024, which is 387200.0% up from last year.
  • Recursion Pharmaceuticals' FCF Margin amounted to 2272.52% in Q3 2025, which was down 20279600.0% from 413.92% recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' FCF Margin peaked at 1369.7% during Q1 2022, and registered a low of 2590.68% during Q4 2021.
  • Its 5-year average for FCF Margin is 988.37%, with a median of 699.37% in 2023.
  • Within the past 5 years, the most significant YoY rise in Recursion Pharmaceuticals' FCF Margin was 288767300bps (2021), while the steepest drop was -27722500bps (2021).
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' FCF Margin stood at 2590.68% in 2021, then surged by 85bps to 385.54% in 2022, then crashed by -81bps to 699.15% in 2023, then crashed by -267bps to 2567.71% in 2024, then grew by 11bps to 2272.52% in 2025.
  • Its last three reported values are 2272.52% in Q3 2025, 413.92% for Q2 2025, and 907.35% during Q1 2025.